Innovating Works
SC1-PHE-CORONAVIRUS-2020-...
SC1-PHE-CORONAVIRUS-2020-2E: Networking of existing EU and international cohorts of relevance to COVID-19
Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 11-06-2020.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.


Scope:Proposals under this coordination and support action should support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals. This effort should contribute to help in the identification of key factors influencing... ver más

Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.


Scope:Proposals under this coordination and support action should support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals. This effort should contribute to help in the identification of key factors influencing the susceptibility to infection and clinical manifestation, to assess the optimized therapeutic and clinical management options, and to derive lessons on the health and socio-economic impacts of the pandemic. They should develop cohort readiness to adapt rapidly to future crisis. Proposals should consider strategies to interact with the COVID-19 cohort(s) that will be funded under this expression of interest and international initiatives on cohorts, as well as liaising with the network of clinical trials on COVID-19.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow these specific challenges to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected Impact:Pooling of data from multiple existing cohorts that will inform on key aspects related to COVID-19 and provide evidence-based recommendations for health policies in preventive strategies, protective actions, and disease management.Creating a cohort framework to rapidly address pandemics in the future.
Cross-cutting Priorities:Open InnovationGenderSocio-economic science and humanities


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens. Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and various factors that might be associated to the perturbation of health. Such existing cohorts might provide key information relevant to COVID-19, including on risk factors, the benefits and risks of healthcare interventions including medicines and on the impact of vaccination. However, the challenge is to be able to identify and extract a sufficiently high number of cases with corresponding high-quality data that can be used across the different cohorts. Consequently, existing cohorts should be brought together in a common effort to standardize data associated to COVID-19 and extract information that will help ensuring optimal prevention, protection and treatment of citizens.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
1. Eligible countries: described in Annex A of the Work Programme.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness...
1. Eligible countries: described in Annex A of the Work Programme.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Annex K of the Work Programme on Actions involving financial support to third parties.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
7. Additional obligations
Data sharing
Beneficiaries in grants awarded under this call for expression of interest must make available their research data, at the latest within 30 days after it has been generated, through open access or, if agreed by the Commission, by giving access rights to those third parties that need the research data to address the public health emergency. Therefore the relevant option of Article 29.3 (option 1c) of the H2020 Model Grant Agreement will apply.
The use of harmonised protocols in collaboration with other actors is recommended for this purpose.
Beneficiaries must make the research data accessible and re-usable through appropriate platforms (such as the data-sharing platform), following guidelines communicated by the Commission.
The relevant option of Article 29.1 of the H2020 Model Grant Agreement will apply.
It is expected that quality-controlled data are shared in accordance with the FAIR principles.
A draft data management plan (DMP) must be submitted preferably with the proposal and at the latest before the signature of the grant agreement. The DMP should address the relevant aspects of making the data FAIR – findable, accessible, interoperable and re-usable, including what data the project will generate, whether and how the data will be made accessible for verification and re-use, and how it will be circulated and preserved. A template for such a plan is given in the guidelines on data management in the H2020 Online Manual.
Costs related to data management and data sharing are eligible for reimbursement if incurred during the project duration under the conditions set out in the grant agreement.
Exploitation obligations
In the context of the public health emergency, additional exploitation obligations apply, to ensure that results or resulting products/services (i.e. products or services developed based on results generated in the action) will be available and accessible, as soon as possible and at fair conditions. This will include an obligation to license on a non-exclusive basis and at fair and reasonable conditions.
The scope of the additional exploitation obligations will be discussed in more detail with successful applicants/participants at due time.
To enhance the exploitation of results, beneficiaries must provide a "results ownership list" (ROL) together with the final report and use the Horizon results platform.
The option of Article 28.1 of the Model Grant Agreement will apply and the necessary provisions will be inserted in Annex 1.
Right to object to transfers of ownership and exclusive licences
The relevant option of Article 30.3 of the H2020 Model Grant Agreement will apply.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-SC1-PHE-CORONAVIRUS-2020-2 Networking of existing EU and international cohorts of relevance to COVID-19 Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and...
Sin info.
SC1-PHE-CORONAVIRUS-2020-2D Pan-European COVID-19 cohorts
en consorcio: Specific Challenge:The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-PHE-CORONAVIRUS-2020-2C Behavioural, social and economic impacts of the outbreak response
en consorcio: Scope:Proposals should focus on lessons learnt: they should i) address how to mitigate social and economic impacts of the outbreak response...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-PHE-CORONAVIRUS-2020-2E Networking of existing EU and international cohorts of relevance to COVID-19
en consorcio: Specific Challenge:Several large-scale cohorts are supported in Europe and the world with valuable information on health of individuals and...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-PHE-CORONAVIRUS-2020-2B Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)
en consorcio: Scope:Innovation Actions of one of the following two categories to: 1) Support solutions that are close-to-market (TRL 7) in one of the COV...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
SC1-PHE-CORONAVIRUS-2020-2A Repurposing of manufacturing for vital medical supplies and equipment.
en consorcio: Scope:Proposals for innovation actions targeted under this topic should address the re-orientation and repurposing of production capacities...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de